Retension Pharmaceuticals to Participate in Guggenheim Healthcare Innovation Conference

FALLS CHURCH, Va., Nov. 05, 2026 /CourierPR/ -- Retension Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing medicines for hypertension and other cardiovascular diseases, will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference. The event, taking place from November 9 to 11, 2026, in Boston, Massachusetts, will feature management from Retension Pharmaceuticals in a fireside chat scheduled for Tuesday, November 10, at 7:30 a.m. Eastern Time.

Retension Pharmaceuticals is developing RTN-001, a cardiovascular-targeted, next-generation PDE5 inhibitor. This innovative drug is designed to enhance nitric oxide signaling in central arteries, addressing a core driver of hypertension. RTN-001 is being developed under an exclusive worldwide license from Sanofi S.A. The company has conducted multiple clinical trials involving 265 enrolled subjects. In two Phase 2 pilot trials, RTN-001 demonstrated clinically meaningful reductions in systolic and diastolic blood pressure in patients with hypertension. A Phase 2b trial of RTN-001 in hypertension is currently ongoing.

The company's participation in the Guggenheim 3rd Annual Healthcare Innovation Conference underscores its commitment to advancing the treatment of cardiovascular diseases. The fireside chat will provide an opportunity for the company to discuss its latest developments and future plans with industry experts and attendees. A live webcast of the event will be available on the “News & Events” page in the Investor Relations section of the Retension Pharmaceuticals website.